Serum Albumin-Peptide Conjugates for Simultaneous Heparin Binding and Detection

Qing Liu, Salla Välimäki, Ahmed Shaukat, Boxuan Shen, Veikko Linko, Mauri A. Kostiainen*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

16 Citations (Scopus)
146 Downloads (Pure)


Heparin is a polysaccharide-based anticoagulant agent, which is widely used in surgery and blood transfusion. However, overdosage of heparin may cause severe side effects such as bleeding and low blood platelet count. Currently, there is only one clinically licensed antidote for heparin: Protamine sulfate, which is known to provoke adverse effects. In this work, we present a stable and biocompatible alternative for protamine sulfate that is based on serum albumin, which is conjugated with a variable number of heparin-binding peptides. The heparin-binding efficiency of the conjugates was evaluated with methylene blue displacement assay, dynamic light scattering, and anti-Xa assay. We found that multivalency of the peptides played a key role in the observed heparin-binding affinity and complex formation. The conjugates had low cytotoxicity and low hemolytic activity, indicating excellent biocompatibility. Furthermore, a sensitive DNA competition assay for heparin detection was developed. The detection limit of heparin was 0.1 IU/mL, which is well below its therapeutic range (0.2-0.4 IU/mL). Such biomolecule-based systems are urgently needed for next-generation biocompatible materials capable of simultaneous heparin binding and sensing.

Original languageEnglish
Pages (from-to)21891-21899
JournalACS Omega
Issue number26
Publication statusPublished - 2019
MoE publication typeA1 Journal article-refereed


Dive into the research topics of 'Serum Albumin-Peptide Conjugates for Simultaneous Heparin Binding and Detection'. Together they form a unique fingerprint.

Cite this